ADAM10 and Alzheimer disease: A mild stimulation of APP shedding by ADAM10 is considered as a possible treatment strategy for AD and has been successfully tested in a recent phase II clinical trial, where acitretin indeed mildly increased sAPPα levels by 25% (Endres et al, 2014).